Voriconazole is not effective against which of the following?

Explanation

## Correct Answer: D. Mucormycosis Voriconazole is a second-generation triazole antifungal with broad-spectrum activity against most yeasts and filamentous fungi, but it has a critical limitation: it is **not effective against Mucorales species** (which cause mucormycosis). This is the key discriminating fact. Mucormycosis, caused by organisms like Rhizopus, Mucor, and Rhizomucor, is intrinsically resistant to all azoles (fluconazole, itraconazole, voriconazole) and echinocandins. The reason lies in the organism's cell wall composition and ergosterol biosynthesis pathway, which differs from other fungi. In India, mucormycosis is an emerging opportunistic infection, particularly in immunocompromised patients (HIV/AIDS, post-transplant, diabetic ketoacidosis). Voriconazole is highly effective against Candida species (including C. albicans and C. tropicalis) and Aspergillus species, making it a first-line agent for invasive aspergillosis and fluconazole-resistant candidiasis. However, for mucormycosis, the **drug of choice is liposomal amphotericin B (L-AmB)**, often followed by posaconazole or isavuconazole for maintenance therapy. This distinction is critical in clinical practice and frequently tested in NEET PG. ## Why the other options are wrong **A. Candida albicans** — Candida albicans is highly susceptible to voriconazole. Voriconazole is a first-line agent for invasive candidiasis and fluconazole-resistant C. albicans infections. This option represents a classic use of voriconazole in Indian clinical practice, making it an incorrect answer to a question asking what voriconazole is NOT effective against. **B. Candida tropicalis** — Candida tropicalis is another Candida species that is susceptible to voriconazole. Like C. albicans, C. tropicalis is commonly encountered in Indian hospitals (particularly in ICU settings and immunocompromised patients) and responds well to voriconazole therapy. This is a distractor that tests whether students know voriconazole's spectrum. **C. Aspergillosis** — Aspergillus species (A. fumigatus, A. flavus, A. niger) are highly susceptible to voriconazole, which is the preferred agent for invasive aspergillosis in India. Voriconazole has superior CNS penetration compared to amphotericin B, making it ideal for aspergillus meningitis. This option is a major indication for voriconazole, not a limitation. ## High-Yield Facts - **Mucormycosis** is intrinsically resistant to all azoles (fluconazole, itraconazole, voriconazole) and echinocandins. - **Liposomal amphotericin B (L-AmB)** is the drug of choice for mucormycosis; posaconazole or isavuconazole are alternatives for maintenance therapy. - **Voriconazole** is the preferred agent for invasive aspergillosis and has superior CNS penetration compared to amphotericin B. - **Voriconazole** is effective against Candida species (C. albicans, C. tropicalis, C. glabrata) and is used for fluconazole-resistant candidiasis. - **Mucormycosis in India** is increasingly seen in diabetic ketoacidosis, post-transplant patients, and those with hematologic malignancies. ## Mnemonics **Voriconazole Spectrum (VAC)** **V**oriconazole works against: **A**spergillus, **C**andida. Does NOT work against **M**ucor (remember: Voriconazole = VAC, not VACM). **Antifungal Choice for Mucor** **L-AmB First, Posaconazole Later** — Liposomal amphotericin B is induction therapy for mucormycosis; posaconazole/isavuconazole for maintenance. Azoles (including voriconazole) are useless. ## NBE Trap NBE pairs voriconazole with broad-spectrum activity to lure students into thinking it covers all fungi. The trap is that students may confuse voriconazole's excellent coverage of Candida and Aspergillus with coverage of Mucorales, forgetting that intrinsic resistance to azoles is a defining feature of Mucormycosis. ## Clinical Pearl In Indian ICUs, a patient with diabetes presenting with rapid-onset rhinocerebral infection or pulmonary infiltrates should raise suspicion for mucormycosis—voriconazole will fail, and L-AmB must be started immediately. Early recognition and amphotericin B initiation are lifesaving in this high-mortality condition. _Reference: KD Tripathi Pharmacology Ch. 49 (Antifungal Agents); Harrison Ch. 212 (Mucormycosis)_